CALQUENCE^®
(acalabrutinib, as maleate)
ASTRAZENECA
HK Reg. No. HK- 68724 (17 Jun, 2025)
Composition:¹

• Each hard capsule contains 100 mg of acalabrutinib

Indication:¹

• Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL)

• Calquence in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL)

• Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy

• Calquence in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant (ASCT)

• Calquence as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) not previously treated with a Bruton tyrosine kinase (BTK) inhibitor

References

1. EMA. CALQUENCE Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/calquence-epar-product-information_en.pdf. [Accessed 18 July 2025].